MEDANTA

Global Health Share Price

 

 

Invest in Global Health with 3.32X leverage

Invest with MTF

Performance

  • Low
  • ₹1,103
  • High
  • ₹1,149
  • 52 Week Low
  • ₹1,010
  • 52 Week High
  • ₹1,457
  • Open Price₹1,103
  • Previous Close₹1,108
  • Volume181,865
  • 50 DMA₹1,153.85
  • 100 DMA₹1,197.50
  • 200 DMA₹1,215.60

Investment Returns

  • Over 1 Month -5.48%
  • Over 3 Month -10.78%
  • Over 6 Month -14.63%
  • Over 1 Year -2.21%

Smart Investing Starts Here Start SIP with Global Health for Steady Growth!

Invest Now

Global Health Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 59.8
  • PEG Ratio
  • 47
  • Market Cap Cr
  • 30,715
  • P/B Ratio
  • 8.3
  • Average True Range
  • 42.52
  • EPS
  • 21.07
  • Dividend Yield
  • 0
  • MACD Signal
  • -23.55
  • RSI
  • 53.29
  • MFI
  • 60.07

Global Health Financials

Global Health Technicals

EMA & SMA

Current Price
₹1,142.70
+ 35 (3.16%)
pointer
  • Bearish Moving Average 7
  • Bullish Moving Average 9
  • 20 Day
  • ₹1,114.58
  • 50 Day
  • ₹1,153.85
  • 100 Day
  • ₹1,197.50
  • 200 Day
  • ₹1,215.60

Resistance and Support

1131.47 Pivot Speed
  • R3 1,206.23
  • R2 1,177.57
  • R1 1,160.13
  • S1 1,114.03
  • S2 1,085.37
  • S3 1,067.93

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Global Health Ltd. is an Australian healthcare technology company providing software solutions that connect clinicians and consumers. Its applications streamline healthcare delivery across hospitals, GPs, and allied health sectors, improving health outcomes through secure data sharing and connected health records.

Global Health has an operating revenue of Rs. 4,004.74 Cr. on a trailing 12-month basis. An annual revenue growth of 13% is good, Pre-tax margin of 18% is great, ROE of 14% is good. The company has a reasonable debt to equity of 8%, which signals a healthy balance sheet. The stock from a technical standpoint is trading below to its key moving averages. It needs to take out these levels and stay above it to make any meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 74 which is a FAIR score but needs to improve its earnings, a RS Rating of 47 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at B- which is evident from recent demand for the stock, Group Rank of 105 indicates it belongs to a poor industry group of Medical-Hospitals and a Master Score of D is close to being the worst. Overall, the stock has mediocre earnings and technical strength, there are superior stocks in the current market environment.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Global Health Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2026-02-04 Quarterly Results
2025-11-07 Quarterly Results
2025-08-07 Quarterly Results
2025-05-15 Audited Results & Final Dividend
2025-02-04 Quarterly Results
Date Purpose Remarks
2025-08-22 FINAL Rs.0.50 per share(25%)Final Dividend
View Global Health Dividend History Arrow

Global Health F&O

Global Health Shareholding Pattern

33.01%
13.12%
0.61%
10.54%
0%
5.95%
36.77%

About Global Health

  • NSE Symbol
  • MEDANTA
  • BSE Symbol
  • 543654
  • Chairman & Managing Director
  • Dr. Naresh Trehan
  • ISIN
  • INE474Q01031

Similar Stocks to Global Health

Global Health FAQs

Global Health share price is ₹1,142 As on 07 February, 2026 | 07:57

The Market Cap of Global Health is ₹30714.7 Cr As on 07 February, 2026 | 07:57

The P/E ratio of Global Health is 59.8 As on 07 February, 2026 | 07:57

The PB ratio of Global Health is 8.3 As on 07 February, 2026 | 07:57

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23